KR101830977B1 - Oral complex formulation comprising omega-3 fatty acid or ester thereof and HMG-CoA reductase inhibitor - Google Patents

Abstract

The present invention relates to a combination preparation for oral use, and more particularly to a soft capsule core comprising an omega-3 fatty acid or an ester thereof; A first coating layer comprising a waterproof coating substrate and surrounding said core; And a second coating layer comprising an HMG-CoA reductase inhibitor and magnesium carbonate or magnesium hydroxide, and surrounding the first coating layer. The combined oral preparation according to the present invention shows that 80% or more of the HMG-CoA reductase inhibitor is released within 30 minutes and does not show delayed release even after storage for 6 months under the conditions of 40 ° C and 75% relative humidity (RH) As a therapeutic agent, it can be usefully used as a combined preparation for treating hyperlipemia easily because it can increase the blood HDL level and lower the LDL and TG levels.

Description

An omega-3 fatty acid or ester thereof and a hydroxymethylglutanyl coenzyme A reductase inhibitor are provided. The omega-3 fatty acid or ester thereof and the HMG-

The present invention relates to an oral combination preparation comprising an HMG-CoA reductase inhibitor having a high emetic rate and exhibiting no delay in release even after storage for a long period of time and containing an omega-3 fatty acid or ester thereof and HMG-CoA reductase inhibitor .

Marine oils, commonly referred to as fish oil, contain two omega-3 fatty acids known to modulate lipid metabolism, eicosapentaenoic acid (EPA) and docosahexaenoic acid (docosahexaenoic acid) (DHA) is a good source. Omega-3 fatty acids lower serum triglycerides (TG), raise serum HDL-cholesterol, lower systolic and diastolic blood pressure and pulse rate, and lower blood clotting factor phospholipid complex activity. In addition, up to now, omega-3 fatty acids have been judged to be tolerated without causing any side effects. Omega-3 fatty acids, which are currently sold as prescription drugs, are omega-3 fatty acid esters, which are polyunsaturated fatty acids from fish oil containing DHA and EPA, Is an esterified concentrate and is marketed under the OMACOR trademark. Omega-3 fatty acid esters of this type are described in U.S. Patent Nos. 5,502,077, 5,656,667 and 5,698,594, which are in the form of soft capsules of gelatinous material.

It is well known that high blood cholesterol is a major risk factor for coronary heart disease (CHD). Prior to 1987, lipid-lowering therapy devices were substantially restricted to low-saturated fat and cholesterol meals, bile acid suppressants (cholestyramine and cholestipol), nicotinic acid (niacin), fibrates and probucol. With the introduction of lovastatin (MEVACOR; see U.S. Patent No. 4,231,938), the first inhibitor of HMG-CoA reductase inhibitor became available for the prescription of 1987, and for the first time, doctors will not have plasma cholesterol It was possible to reduce it to a relatively large extent.

In addition to the natural fermentation products, mevastatin and lovastatin, there are currently available simvastatin (ZOCOR; see US Patent No. 4,444,784), pravastatin sodium salt (PRAVACHOL; see US Patent No. 4,346,227), fluvastatin sodium salt (LESCOL; 5,354,772), atorvastatin calcium salt (LIPITOR; US Patent No. 5,273,995), cerivastatin sodium salt (ribastatin; see US Patent No. 5,177,080), rosuvastatin calcium salt (CRESTOR; 10-0105431) and pitavastatin calcium salt (Livaro; Korean Patent No. 10-0101149). In addition, there are various semisynthetic and fully synthetic HMG-CoA reductase inhibitors. The HMG-CoA reductase inhibitor described above belongs to a structural class of compounds comprising a moiety that may exist as a 3-hydroxy lactone ring or the corresponding ring-opened dihydroxy open acid, often referred to as "statins" Loses. Typically, statin monotherapy has been used to maintain cholesterol levels at normal levels. Statins reduce cholesterol by slowing the production of cholesterol by inhibiting the enzyme HMG-CoA reductase, which regulates the cholesterol production rate of the body, or by increasing liver capacity to remove LDL cholesterol already in the blood. Therefore, the main effect of statins is to lower LDL cholesterol. Statins are known to reduce CHD risk by about a third. However, statins have limited effects on TG and HDL.

Most of these HMG-CoA reductase inhibitors are designed to release rapidly in the gastrointestinal tract. HMG-CoA reductase inhibitors are rapidly absorbed in the small intestine, and Tmax is 4 hours for simvastatin, 1 to 2 hours for atorvastatin, less than 1 hour for pitavastatin and 3 to 5 hours for rosuvastatin It is fast.

In particular, when an amorphous raw material such as rosuvastatin or pitavastatin is used as an HMG-CoA reductase inhibitor, since the main component is hydrolyzed and a lactone-type flexible substance is generated as a hydrolysis product, rosuvastatin Crestor, a commercially available formulation, contains a stabilizing composition.

And patients with cholesterol and multiple dyslipidemia have elevated LDL and TG levels. The combined administration of omega-3 fatty acid esters and statins has the advantage of being applicable when such high LDL and triglyceride levels are seen. There is also a continuing need for commercially available statin pharmaceutical compositions that include a number of statin formulations but which exhibit improved bioavailability, ease of formulation and administration, and ingredients that enhance statin's hypercholesterolemia-suppressing effect. Therefore, when a combination of omega-3 fatty acid ester and statin is developed as a combination drug, it is advantageous to formulate it efficiently because it can raise blood HDL levels and lower LDL and TG levels as a therapeutic agent for hyperlipidemia.

Because of the advantages of the combined use of both drugs, a combination of prescription drugs such as omega-3 fatty acid esters has been extensively studied. However, when the omega-3 fatty acid ester and the statin-based drug are mixed directly, there is a problem that the stability between the two drugs can not be completely guaranteed.

Accordingly, the present inventors have included an omega-3 fatty acid ester and an HMG-CoA reductase inhibitor which have an emission rate equivalent to that of a commercial product of an HMG-CoA reductase inhibitor and do not exhibit a delay in release even after long-term The inventors of the present invention have found that a soft capsule core comprising omega-3 fatty acid esters can be coated with a separation membrane containing a waterproof coating base material and then a drug layer containing a specific coating base material and an HMG-CoA reductase inhibitor CoA reductase inhibitor not only has a rapid release rate but also exhibits no delay in release even after storage under accelerated and harsh conditions and produces a stable combination of omega-3 fatty acid ester and HMG-CoA reductase inhibitor The present invention has been completed.

The present invention relates to an omega-3 fatty acid or its ester and an HMG-CoA reduction method for easily treating hyperlipemia because it can increase the blood HDL level and lower the LDL and TG levels as a therapeutic agent for hyperlipidemia, An enzyme inhibitor is provided.

In addition, the present invention provides a method for producing the oral combination preparation.

In addition, the present invention provides a pharmaceutical composition for preventing or treating hyperlipemia, which comprises the oral combination preparation.

In order to solve the above problems, the present invention provides a soft capsule core comprising an omega-3 fatty acid or an ester thereof; A first coating layer comprising a waterproof coating substrate and surrounding said core; And a second coating layer comprising an HMG-CoA reductase inhibitor and magnesium carbonate or magnesium hydroxide, and surrounding the first coating layer.

The term "omega-3 fatty acid" as used herein refers to natural or synthetic omega-3 fatty acids, and pharmaceutically acceptable esters, derivatives, precursors or salts thereof, and mixtures thereof. Examples of omega-3 fatty acids include eicosapenta-5,8,11,14,17-econic acid (hereinafter referred to as 'EPA'), docosahexa-4,7,10,13,16,19- 'DHA') and omega-3 polyunsaturated long chain fatty acids such as? -Linolenic acid; Esters of glycerol and omega-3 fatty acids such as mono-, di-, and triglycerides; Esters of primary alcohols with omega-3 fatty acids such as fatty acid methyl esters and fatty acid ethyl esters; Precursors of omega-3 fatty acid oils such as EPA and DHA precursor a-linolenic acid; And derivatives such as polycondensed derivatives or polyoxyethylene derivatives. Preferably the omega-3 fatty acids are EPA or DHA, their triglycerides, their ethyl esters and mixtures thereof. Omega-3 fatty acids or their esters, derivatives, precursors, salts and mixtures thereof may be used in pure form or as a component of an oil such as fish oil, preferably a highly refined fish oil concentrate, perilla oil, or marine microalgae oil .

The omega-3 fatty acid or ester thereof of the present invention has the form of a soft capsule and constitutes the core of the oral combination preparation of the present invention.

The term 'first coating layer' used in the present invention means a layer coated with the surface of the core. Although the combination of omega-3 fatty acids and HMG-CoA reductase inhibitor has the advantage of being effective in treatment, various components including omega-3 fatty acids affect the HMG-CoA reductase inhibitor, There is a limitation in practical use. However, in the present invention, since the first coating layer includes the waterproof base material, it is possible to prevent various components including moisture of the core soft capsule from affecting the HMG-CoA reductase inhibitor contained in the second coating layer Feature.

Wherein the waterproof coating base material is at least one selected from the group consisting of hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, polyvinyl pyrrolidone-vinyl acetate copolymer and ethyl cellulose desirable. More preferably, ethylcellulose can be used. According to one embodiment of the present invention, it was confirmed that the material containing ethyl cellulose in the waterproof coating substrate is significantly less flexible than in the case of not containing ethyl cellulose.

The first coating layer may include 1 to 20 parts by weight based on 100 parts by weight of the core. When the amount is less than 1 part by weight, the endothelial coating layer becomes too thin to affect separation and water transfer between the two drugs, and the effect of suppressing the generation of the drug substance is remarkably lowered. In addition, in the case of more than 20 parts by weight, the combined effect of the omega-3 fatty acid and the HMG-CoA reductase inhibitor is remarkably lowered because the thickness of the first coating layer becomes too thick.

The term 'second coating layer' used in the present invention means a layer coated with the surface of the first coating layer. The second coating layer comprises a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor. The HMG-CoA reductase inhibitor means a drug used for the treatment of hyperlipidemia, hypercholesterolemia, and atherosclerosis, because it has a blood lipid concentration and a cholesterol lowering effect by preventing HMG-CoA from being reduced to mevalonate . In the present invention, any one or a pharmaceutically acceptable salt thereof selected from the group consisting of simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin and pitavastatin may be used as the HMG-CoA reductase inhibitor . Preferably rosuvastatin can be used. And 0.5 to 2 parts by weight of the HMG-CoA reductase inhibitor to 100 parts by weight of the core.

Wherein the second coating layer substrate is a substrate coated with an HMG-CoA reductase inhibitor, wherein the second coating layer substrate is a substrate coated with an HMG-CoA reductase inhibitor selected from the group consisting of hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyethylene glycol and polyvinylpyrrolidone-polyethylene glycol graft polymer Any one or more selected can be used. The second coating layer substrate contributes to the rapid release of the HMG-CoA reductase inhibitor and prevents the release of the HMG-CoA reductase inhibitor from being delayed during storage.

In addition, the second coating layer includes magnesium carbonate or magnesium hydroxide. The HMG-CoA reductase inhibitor is disadvantageous in that the HMG-CoA reductase inhibitor is hydrolyzed due to its chemical structure, and a lactone structure is formed as a product of hydrolysis, thereby decreasing the efficacy of the HMG-CoA reductase inhibitor. Accordingly, the present invention is characterized in that the addition of magnesium carbonate or magnesium hydroxide inhibits the hydrolysis of the HMG-CoA reductase inhibitor, thereby inhibiting the production of a flexible substance. Since the oral combination preparation of the present invention contains the HMG-CoA reductase inhibitor together with the omega-3 fatty acid, it is possible to inhibit the hydrolysis of the HMG-CoA reductase inhibitor, Choosing is important. According to one embodiment of the present invention, it was confirmed that magnesium carbonate or other materials similar to magnesium hydroxide (for example, CaCO ₃ ) can not effectively inhibit the generation of a flexible substance.

And 1 to 15 parts by weight of the magnesium carbonate or magnesium hydroxide is preferably included relative to 100 parts by weight of the second coating layer. If the content of magnesium carbonate or magnesium hydroxide is less than 1 part by weight, the effect of suppressing the production of a flexible substance is remarkably lowered. If the content of magnesium carbonate or magnesium hydroxide exceeds 15 parts by weight, precipitation of magnesium carbonate or magnesium hydroxide may occur. More preferably, it comprises 4 to 7.5 parts by weight of magnesium carbonate or magnesium hydroxide per 100 parts by weight of the core. According to one embodiment of the present invention, it is confirmed that when magnesium carbonate or magnesium hydroxide is contained in an amount of 4 to 7.5 parts by weight, formation of a flexible substance can be remarkably suppressed compared with other contents.

It is preferable that the second coating layer comprises 5 to 20 parts by weight based on 100 parts by weight of the core. When the amount of the HMG-CoA reductase inhibitor is less than 5 parts by weight, the combined effect of the omega-3 fatty acid and the HMG-CoA reductase inhibitor is remarkably lowered. When the amount of the HMG-CoA reductase inhibitor is more than 20 parts by weight, the content of the HMG-CoA reductase inhibitor is increased and a large amount of the soft substance is produced. More preferably, the second coating layer comprises 10 to 15 parts by weight based on 100 parts by weight of the core.

The oral combination preparation may further comprise a pharmaceutically acceptable additive, and an appropriate amount of a commonly used disintegrant, diluent, stabilizer, binder and lubricant may be used.

The oral combination preparation according to the present invention can be prepared in the form of tablets coated according to a conventional formulation method. By way of example, the steps of preparing a soft capsule core comprising an omega-3 fatty acid or ester thereof; Coating the core with a coating liquid prepared by dissolving a waterproof base material in a suitable solvent for coating (for example, a mixed solvent of ethanol and water), and then drying to form a first coating layer; Hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyethylene glycol, and polyvinyl alcohol-polyethylene glycol graft polymer, an HMG-CoA reductase inhibitor and magnesium carbonate or magnesium hydroxide in an appropriate solvent (For example, a mixed solvent of ethanol and water), followed by drying the coated core with the first coating layer formed thereon to form a second coating layer, according to the present invention.

In addition, the present invention provides a pharmaceutical composition for preventing or treating hyperlipemia, which comprises the oral combination preparation.

The combined oral preparation according to the present invention releases more than 80% of the HMG-CoA reductase inhibitor within 30 minutes of the release test (0.05M citrate buffer) and releases even after storage for 6 months at 40 ° C and 75% relative humidity (RH) It can be usefully used as a combined preparation for treating hyperlipemia because it does not show a delay phenomenon, can increase the HDL level in the blood and can lower the LDL and TG levels.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing the water absorption rate of the preparations of Examples 1-1 to 1-3. FIG.
FIG. 2 is a graph showing the dissolution rate of Crestor, the control agent of rosuvastatin, and the formulation of Examples 1-1, 2-4 and 3-2.
FIG. 3 shows a dissolution rate graph of Crestor, which is a control agent of rosuvastatin, and the products of Examples 2-1 to 2-4.
FIG. 4 is a graph showing the initial dissolution rate and the dissolution rate at 1, 3, and 6 months of accelerated aging of Crestor, which is a control agent of rosuvastatin, and Example 2-1.
FIG. 5 is a graph showing the initial dissolution rate and the dissolution rate at 1, 3, and 6 months of accelerated Crestor and Example 2-4 of Roche versus statin.
6 is a graph showing the initial dissolution rate and the dissolution rate at 1, 3, and 6 months of accelerated aging of Crestor, which is a control agent of rosuvastatin, and Example 3-1.
FIG. 7 is a graph showing the initial dissolution rate and the dissolution rate at 1, 3, and 6 months of accelerated aging of Crestor, the control agent of rosuvastatin, and the preparation of Example 3-2.
FIG. 8 is a graph showing the initial dissolution rate of Crestor, which is a control agent of rosuvastatin, and the dissolution rate at 1, 3, and 6 months of acceleration.
9 is a graph showing changes in contents of crestor, which is a control agent of rosuvastatin, and the initial and accelerated 1, 3, and 6 months of Examples 2-1, 2-4, 3-1, and 3-2 formulations.
10 is a graph showing changes in individual flexible substances at the initial stage and at the accelerated 1, 3, and 6 months of the preparation of Example 2-1.
11 is a graph showing changes in individual flexible substances at the initial stage and at the accelerated 1, 3, and 6 months of the formulation of Example 2-4.
Fig. 12 is a graph showing changes in individual flexible substances at the initial stage and at the accelerated 1, 3, and 6 months of the preparation of Example 3-1.
FIG. 13 is a graph showing changes in individual flexible substances at the initial stage and at the accelerated 1, 3, and 6 months of the preparation of Example 3-2.
FIG. 14 is a graph showing the change of individual soft substances at the initial and accelerated 1, 3, and 6 months of Crestor, the control preparation of rosuvastatin.
Fig. 15 is a graph showing changes in the total soft matter of Crestor, which is a control agent of rosuvastatin, and the initial and accelerated 1, 3, and 6 months of Examples 2-1, 2-4, 3-1, to be.
16 is a graph showing the change in the content of the flexible substances in the initial and accelerated 1, 3, 6, and 3 months, 3R, and 5S lactones of the formulation of Example 4-1 and Comparative Example 1 containing the same amount of stabilizing agent in the rosuvastatin coating layer to be.
17 shows the change in the unkip (unk3; RRT2.59) change of the initial and accelerated 1, 3, 6, and months of the formulation of Example 4-1 and Comparative Example 1 containing the same amount of stabilizer to the rosuvastatin coating layer Fig.
18 is a graph showing the changes in the solubility of 3R and 5S lactone in the initial and accelerated 1, 3, 6, and 3 months according to the amounts of magnesium carbonate or magnesium hydroxide added to the rosuvastatin coating layer.
19 is a graph showing changes in unkip (unk3; RRT2.59) of initial and accelerated 1, 3, 6, and months according to the amount of magnesium carbonate or magnesium hydroxide added to the rosuvastatin coating layer.
20 is a graph showing the initial dissolution rate of Crestor, which is a control agent of rosuvastatin, and Examples 3-2 and 4-1.

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are for further illustrating the present invention, and the scope of the present invention is not limited by these examples.

Example 1: Measurement of disintegration time and water absorption rate according to the first coating layer

In order to measure the disintegration time and the water absorption rate according to the first coating layer of the oral combination preparation, the following procedure was performed.

1) Preparation of Examples 1-1 to 1-3

1,000 mg equivalent of omega-3 fatty acid ester oil and 10 mg of Roche Vastatin were uniformly mixed to prepare a mixture (Example 1-1).

In addition, according to the composition shown in Table 1, hydroxypropylmethylcellulose, polyethylene glycol, polyvinylbrolidone, and ethylcellulose were mixed with a solvent composed of alcohol and water, and then coated using a coater (SEJONG, SFC-30) (Example 1-2) and a coating exhibiting waterproof property (Example 1-3) were prepared.

mg / Capsule Examples 1-2 Example 1-3 HPMC 2910 (P645) 74.0 74.0 PEG6000 10.0 10.0 PVP K-30 10.0 10.0 Ethyl Cellulose - 26.5 (Ethanol) (1036.0) (1036.0) (DW) (444.0) (444.0) Total mass of coater 94.0 120.5

2) Measurement of disintegration time according to kind of first coating layer

The formulation prepared in Example 1-1 (first coating layer member), Example 1-2 (the first coating layer is a general coating) and Example 1-3 (the first coating layer is waterproof) The disintegration test according to the disintegration test was performed, and the results are shown in Table 2 below.

Example Disintegration time Example 1-1 7 minutes 30 seconds Examples 1-2 10 minutes 50 seconds Example 1-3 13 minutes 00 seconds

As shown in Table 2, it can be confirmed that the disintegration was performed in the order of Example 1-1, Example 1-2, and Example 1-3. From the results, it can be seen that the first coating layer containing the water- It can be confirmed that it is blocked.

3) Measurement of water absorption rate according to the kind of the first coating layer

The formulation prepared in Examples 1-1, 1-2, and 1-3 was over-dried and exposed to a high-humidity condition (20 ° C, 45% RH) for a long period of time (1 month) And the degree of absorbing water according to the initial mass was measured and calculated. The results are shown in FIG.

As shown in FIG. 1, it can be seen that the mass growth rate of Example 1-3 is significantly lower than that of Examples 1-1 and 1-2. From the results, it can be seen that the first coating layer containing the water- It can be confirmed that it is blocked.

Example 2 Measurement of dissolution rate according to the second coating layer

In order to measure the dissolution rate according to the second coating layer of the oral combination preparation, the following procedure was performed.

1) Preparation of Examples 2-1 to 2-4

Using the soft capsule prepared in Example 1-2 as a core, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol-polyvinylpyrrolidone, and polyvinylpyrrolidone were mixed with rosuvastatin according to the composition shown in Table 3 below. A polyethylene glycol graft polymer or a mixture thereof was dissolved in a mixed solution of ethanol and water, followed by coating and drying to form a second coating layer.

mg / Capsule Example 2-1 Example 2-2 Example 2-3 Examples 2-4 Rosuvastatin Ca 10.4 10.4 10.4 10.4 HPMC 2910 (P645) 46.0 26.1 10.4 - PEG6000 6.2 6.2 6.2 - Kollicoat IR - - - 52.2 PVP K-30 6.2 26.1 41.8 6.2 (Ethanol) 644.0 644.0 644.0 460.0 (DW) 276.0 276.0 276.0 460.0 Total mass of coater 68.8 68.8 68.8 68.8

In Examples 2-1 to 2-4, the ratio of hydroxypropylmethylcellulose to polyvinylpyrrolidone was about 9: 1 (Example 2-1), 5: 5 (Example 2-2), 2 : 8 (Example 2-3). In Example 2-4, polyvinyl alcohol-polyethylene glycol graft polymer was used instead of hydroxypropylmethylcellulose and polyvinylpyrrolidone. At this time, the coating temperature was adjusted to 45 ° C and the product temperature was adjusted to 30 ° C. After completion of the coating, drying was performed for 30 minutes to remove remaining ethanol and water.

2) Dissolution test according to the type of the second coating layer

Using the preparations of Examples 2-1 to 2-4, a dissolution test was carried out in a dissolution test solution of 0.05 mL of citrate buffer at a rotation speed of 50 rpm by a paddle method of the second pharmacopoeial elution test. Crestor, the original formulation of rosuvastatin, was used as a comparative preparation. After 5, 10, 15, 30, and 45 minutes from the start of the elution, the eluate was taken to calculate the dissolution rate of rosuvastatin, and the dissolution rate graph is shown in FIG.

As shown in FIG. 3, the results of Examples 2-1 to 2-3 show that the higher the proportion of polyvinylpyrrolidone in the ratio of hydroxypropylmethylcellulose to polyvinylpyrrolidone, the higher the dissolution rate I could confirm. In addition, in the case of Example 2-4 in which polyvinyl alcohol-polyethylene glycol graft polymer was used instead of hydroxypropylmethylcellulose and polyvinylpyrrolidone, as compared with Examples 2-1 to 2-3, rosuvastatin Of the original formulation, Crestor.

Based on the above results, the experiment was continued with the same preparation as in Example 2-4 including the polyvinyl alcohol-polyethylene glycol graft polymer.

Example 3: Determination of the dissolution rate, the content of rosuvastatin and the content of the flexible substance according to the combination of the first coating layer and the second coating layer

To measure the dissolution rate and the content of rosuvastatin according to the combination of the first coating layer and the second coating layer of the combined oral preparation, the following procedure was performed.

1) Preparation of Examples 3-1 and 3-2

The same second coating layer as in Example 2-1 (Example 3-1) and the same second coating layer as in Example 2-4 were formed on the same first coating layer as the preparation prepared in Example 1-3, respectively Coating was carried out to prepare a combination preparation for oral use as shown in Table 4 below.

mg / Capsule Example 3-1 Example 3-2 The first coating layer HPMC 2910 (P645) 74.0 74.0 PEG6000 10.0 10.0 PVP K-30 10.0 10.0 Ethyl Cellulose 26.5 26.5 The second coating layer Rosuvastatin Ca 10.4 10.4 HPMC 2910 (P645) 46.0 - PEG6000 6.2 - Kollicoat IR - 52.2 PVP K-30 6.2 6.2

Specifically, a solution of hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol-polyethylene glycol graft polymer, or a mixture thereof is dissolved in a mixed solution of ethanol and water to be coated with rosuvastatin, 2 < / RTI > coating layer to prepare the desired oral combination preparation. At this time, the coating temperature was adjusted to 45 ° C and the product temperature was adjusted to 30 ° C. After completion of the coating, drying was performed for 30 minutes to remove remaining ethanol and water.

2) Measurement of dissolution rate according to the combination of the first coating layer and the second coating layer

The formulation of Example 1-1 in which the first coating layer and the second coating layer were not provided and the formulation of Example 2-4 in which the first coating layer was not a waterproof base and the preparation of Example 3-2 were used, The dissolution rate was measured. 0.05 M citrate buffer In a 900 mL dissolution test, the elution test was conducted at a rotation speed of 50 rpm for the pharmacopoeial elution second paddle method. Crestor, the original formulation of rosuvastatin, was used as a comparative preparation. After 5, 10, 15, 30, and 45 minutes from the start of the elution, the eluate was taken to calculate the dissolution rate of rosuvastatin, and the dissolution rate graph is shown in FIG.

As shown in FIG. 2, it was confirmed that the formulation of Example 1-1 significantly reduced the dissolution rate of rosuvastatin compared to the preparations of Examples 2-4 and 3-2. Further, in the case of the preparations of Examples 2-4 and 3-2, almost the same dissolution rate could be confirmed. From the above results, it can be seen that the kind of the first coating layer itself does not participate in the dissolution rate of the rosuvastatin in the initial stage, and the simple mixture is the dissolution rate of the rosuvastatin in comparison with the formulation having the rosuvastatin control preparation (Crestor) and the first coating layer and the second coating layer It can be confirmed that the speed is slow.

3) Determination of the dissolution rate during the accelerated storage period according to the combination of the first coating layer and the second coating layer

The formulations of Examples 2-1, 2-4 and Examples 3-1 and 3-2 were packaged in high density polyethylene (HDPE) bottles and stored at 40 < 0 > C and 75% relative humidity conditions (accelerated conditions). After 1, 3, and 6 months from the start of the test, the sample was taken and the dissolution rate of rosuvastatin was confirmed in the same manner as in the above test, and the results are shown in FIGS.

As shown in Figs. 4 to 8, it was confirmed that the preparations of Examples 2-1 and 2-4 showed remarkable dissolution deterioration under accelerated conditions. On the other hand, all of the preparations of Examples 3-1 and 3-2 having the first coating layer of the waterproof base exhibit almost no dissolution lowering phenomenon and are stable.

In addition, the preparation of Example 3-2, which was coated with a rosuvastatin drug-containing polyvinyl alcohol-polyethylene glycol graft polymer (Kollicoat IR) after the coating of the first coating layer of the waterproof base and hydroxypropylmethylcellulose (HPMC 2910 P645)) was compared with the preparations of Examples 2-1 and 2-4 in the case of Example 3-1 based on the hydroxypropylmethylcellulose, the rate of decrease of the dissolution rate was small when based on hydroxypropylmethylcellulose , But the formulation exhibiting a dissolution rate similar to that of the control (Crestor) was the formulation of Example 3-2.

4) Measurement of the content change of rosuvastatin according to the combination of the first coating layer and the second coating layer

The formulations of Examples 2-1, 2-4, 3-1 and 3-2 were packaged in HDPE bottles and stored at 40 < 0 > C and 75% relative humidity (accelerated conditions). After 1, 3, and 6 months from the initiation of the test, samples were taken and the content of rosuvastatin was confirmed by reference to the standards and test methods of Roche Vastatin's product (SuBast). The results are shown in Table 5 (unit:%) (w / w)) and FIG. 9.

Crestor 10mg Example 2-1 Examples 2-4 Example 3-1 Example 3-2 Initial 101.0 ± 0.5 100.0 ± 0.9 100.0 ± 1.3 100.0 ± 2.1 100.0 ± 1.1 Accelerated 1 month 102.7 ± 1.0 92.4 ± 5.0 89.0 ± 4.2 98.7 ± 3.7 100.6 ± 3.3 Accelerated 3 months 103.8 ± 2.7 82.6 ± 8.2 78.3 ± 1.1 96.4 ± 1.6 98.9 ± 1.4 Accelerated 6 months 100.5 ± 0.1 78.6 ± 7.5 60.4 ± 5.7 95.2 ± 4.2 98.7 ± 4.6

As shown in Table 5 and FIG. 9, the contents of the preparations of Examples 2-1 and 2-4 all decreased in proportion to the storage period, whereas in Examples 3-1 and 3-2, It is hardly shown and relatively stable. This indicates that the first coating layer of the waterproof base material between the omega-3 fatty acid ester soft capsule and the rosuvastatin drug coating has an effective effect of effectively blocking the conditions such as moisture that may affect the stability.

5) Determination of the change of rosuvastatin in accordance with the combination of the first coating layer and the second coating layer

The formulations of Examples 2-1, 2-4, 3-1 and 3-2 were packaged in HDPE bottles and stored at 40 < 0 > C and 75% relative humidity (accelerated conditions). After 1, 3, and 6 months from the initiation of the test, samples were taken and the rosuvastatin suppositories were identified by reference to the standards and test methods of Roche Vastatin's product (SuBast). The results are shown in the following Tables 6 to 8 (units:% (w / w)) and FIGS. 10 to 15.

Name of flexible material RRT Example 2-1 Examples 2-4 Early Acceleration
1 month Acceleration
3 months Acceleration
6 months Early Acceleration
1 month Acceleration
3 months Acceleration
6 months unk1 0.67 - - - 0.37 - 0.35 1.88 4.08 unk2 0.72 0.12 1.58 2.46 3.02 0.15 4.33 8.90 10.79 B1 0.84 0.30 0.31 0.23 0.34 0.33 0.39 0.16 0.22 B2 1.58 0.12 0.25 0.47 0.60 0.24 0.35 0.58 0.70 3R, 5S lactone 2.22 0.44 2.10 2.82 4.06 0.38 4.90 9.04 11.56 Total flexible material 0.98 4.24 5.98 8.39 1.10 10.32 20.55 27.35

Name of flexible material RRT Example 3-1 Example 3-2 Early Acceleration
1 month Acceleration
3 months Acceleration
6 months Early Acceleration
1 month Acceleration
3 months Acceleration
6 months unk1 0.67 0.45 0.54 0.88 1.12 - - - - unk2 0.72 - 0.68 0.99 1.47 - 0.08 0.13 0.21 B1 0.84 0.31 0.39 0.25 0.42 0.09 0.09 0.09 0.09 B2 1.58 0.05 0.07 0.10 0.20 0.04 0.05 0.08 0.10 3R, 5S lactone 2.22 0.17 0.80 1.30 1.96 0.08 0.26 0.31 0.41 Total flexible material 1.48 2.49 3.53 5.17 0.21 0.48 0.61 0.81

Name of flexible material RRT Crestor 10mg Early Accelerated 1 month Accelerated 3 months Accelerated 6 months B1 0.84 0.09 0.15 0.14 0.14 B2 1.58 0.14 0.22 0.25 0.27 3R, 5S lactone 2.22 - 0.12 0.46 0.46 Total flexible material 0.23 0.48 0.85 0.88

It can be seen from Tables 6 to 8 and 10 to 15 that the preparations of Examples 2-1 and 2-4 all exhibited an increase in the amount of the flexible substance in proportion to the storage period under accelerated storage conditions, whereas Examples 3-1 and 3-2 It is relatively stable. The results indicate that the barrier coating between the omega-3 fatty acid ester soft capsule and the rosuvastatin drug coating has an effective effect of effectively blocking the conditions such as moisture that may affect stability. In particular, in the case of Example 3-2, it is confirmed that a lower level of the flexible substance is produced as compared with the control preparation (Crestor), which is more stable than the control preparation.

The results of the above experiment are summarized to confirm that Example 3-2, which has almost no change in the content and the amount of the flexible substance and has a dissolution rate similar to that of the Roche Vastatin tablet, is the most stable and effective formulation.

Example 4: Determination of a flux and dissolution rate according to magnesium carbonate or magnesium hydroxide

In order to measure the change of the softening material and the dissolution rate depending on the magnesium carbonate or magnesium hydroxide added to the second coating layer, the following procedure was carried out.

1) Preparation of Examples 4-1 to 4-4

Magnesium carbonate or magnesium hydroxide was added to the second coating layer as shown in Table 9 below to prepare the preparations of Examples 4-1 to 4-4. Also, the preparation of Comparative Example 1 was prepared using CaCO ₃ instead of magnesium carbonate or magnesium hydroxide.

Example 4-1 Example 4-2 Example 4-3 Example 4-4 Comparative Example 1 MgCO ₃ 10 mg 5 mg 3 mg - - Mg (OH) ₂ - - - 10 mg - CaCO ₃ - - - - 10 mg

2) Determination of the change of rosuvastatin's solubility during severe and accelerated storage

From the above results, the most stable case was the coating of a waterproof barrier coating of Example 3-2 and a coating of rosuvastatin drug containing polyvinyl alcohol-polyethylene glycol graft polymer (Kollicoat IR). In this case, however, the amount of the softening agent increases with time under the accelerated condition. At this time, the basic stabilizer is mixed with the second coating layer and the coating is carried out in the same manner as described above.

The preparations of Example 3-2, Examples 4-1 to 4-4, and Comparative Example 1 were packaged in a high density polyethylene (HDPE) bottle and stored at 40 ° C and 75% relative humidity (accelerated conditions). After 1, 3, and 6 months from the initiation of the test, samples were taken and the rosuvastatin suppositories were identified by the same method with reference to the standards and test methods of Roche Vastatin's product (SuBast) 11 (unit:% (w / w)), and Figs. 16 to 21.

3R, 5S Lactone flexible material Early Accelerated 1 month Accelerated 3 months Accelerated 6 months Example 4-1 0.04 0.08 0.11 0.19 Example 4-2 0.05 0.08 0.15 0.21 Example 4-3 0.05 0.09 0.13 0.19 Example 4-4 0.05 0.10 0.12 0.15 Comparative Example 1 0.05 0.07 0.10 0.17

unk3 (RRT 2.59) flexible material Early Accelerated 1 month Accelerated 3 months Accelerated 6 months Example 4-1 - - 0.02 0.03 Example 4-2 - - - 0.02 Example 4-3 - - - 0.02 Example 4-4 - - 0.02 0.05 Comparative Example 1 - - 0.03 0.05

As shown in Tables 10 and 11 and Figs. 16 to 21, the preparations of Examples 4-1 to 4-4 containing magnesium carbonate or magnesium hydroxide were the most effective as stabilizers. At this time, 3R, 5S Lactone is less than 1.5%, and unknown substance is less than 0.2% according to Suubast, the product of Roche Vastatin.

In the case of the preparation of Comparative Example 1, it was confirmed that the production of the unknown softening substance was not effectively inhibited as compared with the same content of Example 4-1.

In addition, in the case of the preparations of Examples 2-1, 2-4, 3-1 and 3-2 which did not contain magnesium carbonate or magnesium hydroxide, the flexible substances unk 1 and 2 were produced, while magnesium carbonate or magnesium hydroxide was contained In the case of the preparations of Examples 4-1 to 4-4, it was confirmed that magnesium carbonate or magnesium hydroxide had a function as a stabilizer specific to rosuvastatin, have.

3) Determination of dissolution rate of combination preparation

Example 3-2 in which magnesium carbonate or magnesium hydroxide was not contained and Example 4-2 in which magnesium carbonate was contained was eluted from the dissolution test solution in 900 mL of a citrate buffer solution of 0.05 M in the second paddle method at a rotation rate of 50 rpm . The results are shown in Fig. 20.

As shown in FIG. 20, the preparation of Example 4-2 had a slightly higher dissolution rate than the preparation of Example 3-2, but slightly differed from the initial dissolution rate, but as a result, the dissolution criterion of the rosuvastatin preparation More than 80% elution within 30 minutes).

Claims (11)

A soft capsule core comprising an omega-3 fatty acid or ester thereof;
A first coating layer comprising a waterproof coating substrate and surrounding said core; And
A second coating layer comprising an HMG-CoA reductase inhibitor and magnesium carbonate or magnesium hydroxide, said first coating layer surrounding said first coating layer,
Wherein the HMG-CoA reductase inhibitor is rosuvastatin or a pharmaceutically acceptable salt thereof.
The method of claim 1 wherein said waterproof coating substrate is selected from the group consisting of hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, polyvinylpyrrolidone-vinyl acetate copolymer and ethyl cellulose Or a pharmaceutically acceptable salt thereof.
2. The oral combined preparation according to claim 1, wherein the first coating layer comprises ethyl cellulose.
delete The method of claim 1, wherein the second coating layer comprises at least one selected from the group consisting of hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyethylene glycol, and polyvinylpyrrolidone-polyethylene glycol graft polymer Wherein the composition is an oral preparation.
2. The oral combined preparation according to claim 1, wherein the composition comprises 1 to 20 parts by weight of the first coating layer and 5 to 20 parts by weight of the second coating layer with respect to 100 parts by weight of the core.
The oral combination preparation according to claim 6, further comprising 10 to 15 parts by weight of the second coating layer.
The oral combination preparation according to claim 1, wherein 0.5 to 2 parts by weight of the HMG-CoA reductase inhibitor is added to 100 parts by weight of the core.
The oral combination preparation according to claim 1, wherein 1 to 15 parts by weight of the magnesium carbonate or magnesium hydroxide is contained relative to 100 parts by weight of the second coating layer.
10. The oral combined preparation according to claim 9, wherein 4 to 7.5 parts by weight of the magnesium carbonate or magnesium hydroxide is contained relative to 100 parts by weight of the second coating layer.
A pharmaceutical composition for preventing or treating hyperlipidemia comprising the combination oral preparation according to any one of claims 1 to 3 and 5 to 10.

Images